Mainly based upon criteria for defining clinically insignificant PCa, different centers have set forth variable selection criteria for AS, mostly incorporating low Gleason score (GS), low clinical stage, and low prostate-specific antigen (PSA) level with estimates of tumor volume from biopsy. The gene discussed is KLK3; the disease is posterior cortical atrophy.